Results 151 to 160 of about 69,132 (251)

Tocilizumab for severe and refractory mucous membrane pemphigoid

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Elevated IL‐6 levels identified in mucous membrane pemphigoid support IL‐6 blockade, with tocilizumab demonstrating clinical benefit in nine patients with severe and refractory mucous membrane pemphigoid. Abstract Background Mucous membrane pemphigoid (MMP) is a rare autoimmune blistering disease involving mucous membranes with a potentially ...
Billal Tedbirt, Maud Maho‐Vaillant, Julie Gueudry, Marie‐Laure Golinski, Marion Marcaillou, Blanche Bergeret, Guillaume Chambon, Pierre Bouchetemble, Soumeya Bekri, Abdellah Tebani, Hervé Maillard, Cécile Morice, Anais Vautier, Edgar‐Pierre Libert, Christelle Le Roux‐Villet, Marion Carrette, Olivier Boyer, Vivien Hébert, Sébastien Calbo, André Gillibert, Pascal Joly   +20 more
wiley   +1 more source

Regulation of Immune Checkpoints: From Molecular Mechanisms to Clinical Therapies. [PDF]

MedComm (2020)
Ge Q, Yu L, Lu J, Anwaier A, Xiao X, Chen Y, Ye D, Zhang H, Xu W, Dai W.   +9 more
europepmc   +1 more source

Inflammatory and Immunological Basis of Periodontal Diseases

Journal of Periodontal Research, EarlyView.
The periodontal lesion emerges as an evolving immunological battlefield, where host–microbiome interactions, dysregulated immune responses, fragile resolution mechanisms, and inflammophilic dysbiosis converge to shift the balance from homeostasis to unrestrained tissue destruction.
Giacomo Baima, Marion Arce, Mario Romandini, Thomas Van Dyke   +3 more
wiley   +1 more source

Single-cell transcriptomic insights into the immune heterogeneity of immune checkpoint inhibitors related organ toxicities. [PDF]

Front Immunol
Wen H, Qi Y, Song J, Yan X.
europepmc   +1 more source

Inflammation and mechanical force‐induced bone remodeling

Periodontology 2000, EarlyView.
Abstract Periodontitis arises from imbalanced host–microbe interactions, leading to dysbiosis and destructive inflammation. The host's innate and adaptive immune responses produce pro‐inflammatory mediators that stimulate destructive events, which cause loss of alveolar bone and connective tissue attachment.
Hyeran Helen Jeon, Xin Huang, Leticia Rojas Cortez, Puttipong Sripinun, Jung‐me Lee, Julie J. Hong, Dana T. Graves   +6 more
wiley   +1 more source

Role of CTLA-4 blockade and dacarbazine therapy following anti-PD-1 resistance in melanoma. [PDF]

Discov Oncol
Urbonas V, Dulskas A.
europepmc   +1 more source

Peripheral immune cell subsets as potential predictors of benefit from immune checkpoint blockade therapy in small cell lung cancer. [PDF]

Front Immunol
Galindo-Campos MA, Hardy-Werbin M, Gibert J, Pucci M, Hernández-Prat A, Ríos-Hoyo A, Rocha P, Rossell A, Del Rey-Vergara R, Parreira A, Pellicer A, Taus Á, Rovira A, Arriola E.   +13 more
europepmc   +1 more source

Histiocytes: Multifaceted Regulators of Health and Disease

Veterinary Clinical Pathology, EarlyView.
ABSTRACT The mononuclear phagocyte system encompasses macrophages, dendritic cells (DCs), and monocytes. Tissue‐resident macrophages and dendritic cells arise during embryogenesis and are replenished either through self‐renewal or by monocytes during inflammation.
Erika J. Gruber
wiley   +1 more source

Regulatory T Cells in Hepatocellular Carcinoma: Spatial Niches, Biomarkers, and Clinical Implications. [PDF]

Int J Mol Sci
Liapopoulos D, Sarantis P, Zogas G, Trifylli EM, Bousou TE, Kamitaki K, Anastasiou IA, Kokkali S, Mavromatis S, Koustas E, Elefsiniotis I, Biniari T, Karamouzis MV.   +12 more
europepmc   +1 more source

Integrating Immunotherapy Into Head and Neck Surgery: Bridging Tumor Biology to Perioperative Decision‐Making, a Review

Head &Neck, Volume 48, Issue 9, Page 2570-2583, September 2026.
ABSTRACT Objective To provide a comprehensive review of the biological rationale, clinical evidence, and practical perioperative management of immunotherapy for the head and neck surgeon. Summary Background Data Standard treatment for resectable head and neck squamous cell carcinoma (HNSCC) has reached a survival plateau, with over 50% of patients ...
Nicholas Brian Shannon, Bruce Ashford
wiley   +1 more source